

Luc G T Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4510435/publications.pdf>

Version: 2024-02-01

142
papers

18,470
citations

22132

59
h-index

14197

128
g-index

146
all docs

146
docs citations

146
times ranked

27899
citing authors

#	ARTICLE	IF	CITATIONS
1	Transorbital embolization of cavernous sinus dural arterio-venous malformations with surgical exposure and catheterization of the superior ophthalmic vein. <i>Interventional Neuroradiology</i> , 2023, 29, 715-724.	0.7	1
2	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. <i>Molecular Cancer Research</i> , 2022, 20, 45-55.	1.5	13
3	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
4	Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers. <i>Cancer</i> , 2022, 128, 685-696.	2.0	13
5	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	13.5	223
6	Cytology-based Cancer Surgery of the Head and Neck (CyCaS-HN): a prospective, randomized, controlled clinical trial. <i>European Archives of Oto-Rhino-Laryngology</i> , 2022, 279, 4505-4514.	0.8	1
7	MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer. , 2022, 10, e003917.		19
8	Nodal Metastases in Pediatric and Adult Acinic Cell Carcinoma of the Major Salivary Glands. <i>Otolaryngology - Head and Neck Surgery</i> , 2022, , 019459982210830.	1.1	1
9	Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types. <i>Cancer Research</i> , 2022, 82, 2076-2083.	0.4	18
10	Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. <i>Npj Precision Oncology</i> , 2022, 6, 23.	2.3	17
11	Outcomes Among Patients With or Without Obesity and With Cancer Following Treatment With Immune Checkpoint Blockade. <i>JAMA Network Open</i> , 2022, 5, e220448.	2.8	26
12	Development and Characterization of MYB-NFIB Fusion Expression in Adenoid Cystic Carcinoma. <i>Cancers</i> , 2022, 14, 2263.	1.7	6
13	Cervical Pneumatocele Following Total Thyroidectomy Presenting as an Air Thyrogram. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2022, , .	1.2	0
14	Mutations in KMT2C, BCOR and KDM5C Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 2816.	1.7	3
15	Mitochondrial genotype remodels the metabolic and microenvironmental landscape of H460 cell carcinoma. <i>Science Advances</i> , 2022, 8, .	4.7	15
16	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. <i>JAMA Oncology</i> , 2022, 8, 1352.	3.4	8
17	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. <i>Nature Genetics</i> , 2022, 54, 996-1012.	9.4	30
18	Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38

#	ARTICLE	IF	CITATIONS
19	Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status. <i>Journal of Surgical Oncology</i> , 2021, 123, 141-148.	0.8	5
20	Association of Study Methods and Industry Sponsorship With Inconsistent Performance of Molecular Assays for Indeterminate Thyroid Nodules. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 101.	1.2	0
21	The head and neck cancer genome in the era of immunotherapy. <i>Oral Oncology</i> , 2021, 112, 105040.	0.8	13
22	Nodal disease burden and outcome of medullary thyroid carcinoma. <i>Head and Neck</i> , 2021, 43, 577-584.	0.9	8
23	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	9.4	139
24	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 742-751.	3.0	98
25	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	5.8	212
26	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. <i>International Journal of Cancer</i> , 2021, 149, 139-148.	2.3	1
27	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
28	The role of immune surveillance in malignant transformation of benign salivary gland tumors. <i>Oncotarget</i> , 2021, 12, 592-595.	0.8	2
29	Human Papillomavirus in Patients With Hypopharyngeal Squamous Cell Carcinoma. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, , 019459982110045.	1.1	6
30	Disparities and guideline adherence for HPV testing among patients with oropharyngeal squamous cell carcinoma, NCDB and SEER. <i>Head and Neck</i> , 2021, 43, 2110-2123.	0.9	5
31	Immunologische Signatur und Neoantigen-Landschaft von aggressiven Speicheldrüsenkarzinomen. <i>Laryngo- Rhino- Otologie</i> , 2021, 100, .	0.2	0
32	Immunological Signature and Neoantigene Landscape of aggressive Salivary Gland Cancers. , 2021, 100, .		0
33	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
34	Cytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer. <i>Immunity</i> , 2021, 54, 1037-1054.e7.	6.6	56
35	Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. <i>JAMA Oncology</i> , 2021, 7, 739.	3.4	125
36	Positron Emission Tomography-Computed Tomography Imaging, Genomic Profile, and Survival in Patients With Head and Neck Cancer Receiving Immunotherapy. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2021, 147, 1119-1120.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Flexible fiber-based CO ₂ laser vs monopolar cautery for resection of oral cavity lesions: A single center randomized controlled trial assessing pain and quality of life following surgery. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 690-698.	0.6	2
38	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	1.5	10
39	Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker—Reply. <i>JAMA Oncology</i> , 2021, 7, 1245.	3.4	0
40	HPV Status as Prognostic Biomarker in Head and Neck Cancer—Which Method Fits the Best for Outcome Prediction?. <i>Cancers</i> , 2021, 13, 4730.	1.7	13
41	3p Arm Loss and Survival in Head and Neck Cancer: An Analysis of TCGA Dataset. <i>Cancers</i> , 2021, 13, 5313.	1.7	3
42	Treatment of Early Stage Tonsil Cancer in the Age of Human Papillomavirus—Associated Malignancies. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 165, 104-112.	1.1	2
43	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. <i>American Journal of Cancer Research</i> , 2021, 11, 3628-3644.	1.4	3
44	Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. , 2021, 9, e003683.		9
45	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	1.4	47
46	Human papillomavirus and survival of patients with sinonasal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 1413-1423.	2.0	41
47	Characterizing Relative and Disease-Specific Survival in Early-Stage Cancers. <i>JAMA Internal Medicine</i> , 2020, 180, 461.	2.6	13
48	Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. <i>Cancer</i> , 2020, 126, 994-1003.	2.0	42
49	Association Between Implementation of the 2009 American Thyroid Association Guidelines and De-escalation of Treatment for Low-risk Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 1081.	1.2	10
50	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
51	Molecular Profiling of Thyroid Nodules—Are These Findings Meaningful, or Merely Measurable?. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 845.	1.2	10
52	Augmented reality-enhanced navigation in endoscopic sinus surgery: A prospective, randomized, controlled clinical trial. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 621-629.	0.6	18
53	Racial Disparities in Cancer Presentation and Outcomes: The Contribution of Overdiagnosis. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa001.	1.4	12
54	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46

#	ARTICLE	IF	CITATIONS
55	Assessing the Number of Candidates There Are for Active Surveillance of Low-risk Papillary Thyroid Cancers in the US. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 585.	1.2	9
56	Letter to the Editor: Reversal in Thyroid Cancer Incidence Trends in the United States, 2000-2017. <i>Thyroid</i> , 2020, 30, 1226-1227.	2.4	17
57	Host Factors Independently Associated With Prognosis in Patients With Oral Cavity Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 699.	1.2	28
58	Safety Recommendations for Evaluation and Surgery of the Head and Neck During the COVID-19 Pandemic. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 579.	1.2	430
59	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind" A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	2.0	24
60	DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden. <i>Cell Reports Medicine</i> , 2020, 1, 100034.	3.3	46
61	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 104877.	0.8	22
62	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	3.2	75
63	Active surveillance for patients with very low-risk thyroid cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2020, 5, 175-182.	0.6	28
64	APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 96, 140-147.	0.8	46
65	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
66	Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus. <i>International Journal of Cancer</i> , 2019, 145, 775-784.	2.3	101
67	The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. <i>Histopathology</i> , 2019, 75, 672-682.	1.6	43
68	Lung Cancer Evolution: What's Immunity Got to Do with It?. <i>Cancer Cell</i> , 2019, 35, 711-713.	7.7	6
69	Identification of prognostic molecular biomarkers in 157 HPV-positive and HPV-negative squamous cell carcinomas of the oropharynx. <i>International Journal of Cancer</i> , 2019, 145, 3152-3162.	2.3	48
70	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	15.2	282
71	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
72	Changes in Trends in Thyroid Cancer Incidence in the United States, 1992 to 2016. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2440.	3.8	61

#	ARTICLE	IF	CITATIONS
73	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	15.2	194
74	American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. <i>Head and Neck</i> , 2019, 41, 843-856.	0.9	10
75	Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules. <i>Surgery</i> , 2019, 165, 17-24.	1.0	41
76	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 130-142.	0.8	40
77	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
78	Thyroid Cancer Screening After Nuclear Accidents. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2019, 145, 79.	1.2	1
79	Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1386-1392.	3.0	137
80	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
81	Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. <i>Cancer Cell</i> , 2018, 34, 893-905.e8.	7.7	307
82	The USPSTF Recommendation on Thyroid Cancer Screening. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 755.	1.2	9
83	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
84	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. <i>Clinical Cancer Research</i> , 2017, 23, 5970-5980.	3.2	89
85	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. <i>JAMA Oncology</i> , 2017, 3, 1487.	3.4	146
86	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	5.8	77
87	PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. <i>Cancer Research</i> , 2017, 77, 6365-6374.	0.4	77
88	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	18.5	1,515
89	Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1015.	1.2	359
90	Increases in Thyroid Cancer Incidence and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 389.	3.8	29

#	ARTICLE	IF	CITATIONS
91	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
92	Androgen Receptor Signaling in Salivary Gland Cancer. <i>Cancers</i> , 2017, 9, 17.	1.7	69
93	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	0.8	31
94	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	2.3	569
95	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	0.8	247
96	Robotics in otolaryngology and head and neck surgery: Recommendations for training and credentialing: A report of the 2015 AHNS education committee, AAO-HNS robotic task force and AAO-HNS sleep disorders committee. <i>Head and Neck</i> , 2016, 38, E151-8.	0.9	37
97	Patterns of regional and distant metastasis in esthesioneuroblastoma. <i>Laryngoscope</i> , 2016, 126, 1556-1561.	1.1	57
98	Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. <i>Head and Neck</i> , 2016, 38, E1688-94.	0.9	28
99	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
100	Changing Trends in the Incidence of Thyroid Cancer in the United States. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 709.	1.2	162
101	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4623-4633.	3.2	153
102	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1285-93.	0.9	17
103	Ethical Considerations When Counseling Patients With Thyroid Cancer About Surgery vs Observation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 406.	1.2	12
104	White adipose tissue inflammation and cancer-specific survival in patients with squamous cell carcinoma of the oral tongue. <i>Cancer</i> , 2016, 122, 3794-3802.	2.0	41
105	FAT1 mutations cause a glomerulotubular nephropathy. <i>Nature Communications</i> , 2016, 7, 10822.	5.8	99
106	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. <i>Science Signaling</i> , 2016, 9, ra33.	1.6	54
107	Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base. <i>Cancer</i> , 2016, 122, 1523-1532.	2.0	128
108	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121

#	ARTICLE	IF	CITATIONS
109	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations. <i>Clinical Cancer Research</i> , 2016, 22, 2009-2019.	3.2	70
110	Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 410-415.	0.7	87
111	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. <i>Head and Neck</i> , 2015, 37, 1633-1641.	0.9	7
112	Prognostic Factors in Myoepithelial Carcinoma of Salivary Glands. <i>American Journal of Surgical Pathology</i> , 2015, 39, 931-938.	2.1	68
113	Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. <i>Thyroid</i> , 2015, 25, 865-866.	2.4	7
114	Therapeutic targeting of tumor suppressor genes. <i>Cancer</i> , 2015, 121, 1357-1368.	2.0	132
115	Increasing diagnosis of subclinical thyroid cancers leads to spurious improvements in survival rates. <i>Cancer</i> , 2015, 121, 1793-1799.	2.0	68
116	Wide Inter-institutional Variation in Performance of a Molecular Classifier for Indeterminate Thyroid Nodules. <i>Annals of Surgical Oncology</i> , 2015, 22, 3996-4001.	0.7	124
117	Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 681-687.	2.4	94
118	Decision making in the management of recurrent head and neck cancer. <i>Head and Neck</i> , 2014, 36, 144-151.	0.9	153
119	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. <i>Nature Genetics</i> , 2014, 46, 588-594.	9.4	144
120	A novel tumor: Specimen index for assessing adequacy of resection in early stage oral tongue cancer. <i>Oral Oncology</i> , 2014, 50, 213-220.	0.8	7
121	Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS). <i>Thyroid</i> , 2014, 24, 832-839.	2.4	275
122	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 382-387.	0.3	75
123	Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. <i>Genes and Diseases</i> , 2014, 1, 75-86.	1.5	78
124	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). <i>Oral Oncology</i> , 2014, 50, 947-955.	0.8	51
125	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3
126	Synchronous cancers in patients with head and neck cancer. <i>Cancer</i> , 2013, 119, 1832-1837.	2.0	98

#	ARTICLE	IF	CITATIONS
127	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <i>Nature Genetics</i> , 2013, 45, 253-261.	9.4	324
128	The Increasing Incidence of Thyroid Cancer: The Influence of Access to Care. <i>Thyroid</i> , 2013, 23, 885-891.	2.4	414
129	The mutational landscape of adenoid cystic carcinoma. <i>Nature Genetics</i> , 2013, 45, 791-798.	9.4	394
130	Long-term regional control in the observed neck following definitive chemoradiation for node-positive oropharyngeal squamous cell cancer. <i>International Journal of Cancer</i> , 2013, 133, 1214-1221.	2.3	33
131	The FAT epidemic: A gene family frequently mutated across multiple human cancer types. <i>Cell Cycle</i> , 2013, 12, 1011-1012.	1.3	28
132	First bite syndrome: Incidence, risk factors, treatment, and outcomes. <i>Laryngoscope</i> , 2012, 122, 1773-1778.	1.1	89
133	Predictors of survival and recurrence after temporal bone resection for cancer. <i>Head and Neck</i> , 2012, 34, 1231-1239.	0.9	86
134	Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19024-19029.	3.3	91
135	Predictors of Survival in Mucosal Melanoma of the Head and Neck. <i>Annals of Surgical Oncology</i> , 2011, 18, 2748-2756.	0.7	132
136	Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer. <i>Cancer Causes and Control</i> , 2011, 22, 671-679.	0.8	88
137	High rates of regional failure in squamous cell carcinoma of the hard palate and maxillary alveolus. <i>Head and Neck</i> , 2011, 33, 824-830.	0.9	69
138	Second Primary Cancers After an Index Head and Neck Cancer: Subsite-Specific Trends in the Era of Human Papillomavirus-Associated Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 739-746.	0.8	295
139	Squamous Cell Carcinoma of the Oral Tongue in the Pediatric Age Group. <i>JAMA Otolaryngology</i> , 2010, 136, 697.	1.5	41
140	Ischemic necrosis of the tongue in patients with cardiogenic shock. <i>Laryngoscope</i> , 2010, 120, 1345-1349.	1.1	14
141	Tall-Cell Variant of Papillary Thyroid Carcinoma: A Matched-Pair Analysis of Survival. <i>Thyroid</i> , 2010, 20, 153-158.	2.4	107
142	Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis. <i>American Journal of Surgery</i> , 2010, 200, 454-461.	0.9	168